{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:21:23Z","timestamp":1788805283100,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-04007-8","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T17:44:08Z","timestamp":1724435048000},"page":"73-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 \u0399148\u039c gene polymorphism in patients with type 2 diabetes mellitus"],"prefix":"10.1007","volume":"87","author":[{"given":"Stylianos","family":"Gavriilidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozalia","family":"Andrianopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charikleia","family":"Ntenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sarakapina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Trakatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8844-5631","authenticated-orcid":false,"given":"Antonis","family":"Goulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"4007_CR1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.bbalip.2018.06.018","volume":"1864","author":"P Pingitore","year":"2019","unstructured":"P. Pingitore, S. Romeo, The role of PNPLA3 in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids 1864, 900\u2013906 (2019)","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"4007_CR2","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00125-021-05402-w","volume":"64","author":"W Rathmann","year":"2021","unstructured":"W. Rathmann, B. Bongaerts, Pharmacogenetics of novel glucose-lowering drugs. Diabetologia 64, 1201\u20131212 (2021)","journal-title":"Diabetologia"},{"key":"4007_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29639-5","volume":"8","author":"R Fadaei","year":"2018","unstructured":"R. Fadaei, H. Poustchi, R. Meshkani, N. Moradi, T. Golmohammadi, S. Merat, Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis. Sci Rep 8, 11691 (2018)","journal-title":"Sci Rep"},{"key":"4007_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2174\/1874192401004010297","volume":"4","author":"G Kolovou","year":"2010","unstructured":"G. Kolovou, C. Mihas, K. Anagnostopoulou, V. Kolovou, V. Giannakopoulou, P. Kostakou, M. Stamatelatou, S. Mavrogeni, D. Degiannis, D.P. Mikhailidis, Cholesteryl ester transfer protein gene and effectiveness of lipid lowering of atorvastatin. Open Cardiovasc Med J. 4, 297\u2013301 (2010)","journal-title":"Open Cardiovasc Med J."},{"key":"4007_CR5","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1080\/14656566.2016.1225727","volume":"17","author":"G Mintziori","year":"2016","unstructured":"G. Mintziori, S.A. Polyzos, Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opin Pharmacother 17, 1937\u20131946 (2016)","journal-title":"Expert Opin Pharmacother"},{"key":"4007_CR6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/17512433.2023.2274536","volume":"16","author":"C Tsiampali","year":"2023","unstructured":"C. Tsiampali, P. Papaioannidou, A. Goulas, S.A. Polyzos, The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease. Expert Rev Clin Pharmacol 16, 1063\u20131072 (2023)","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4007_CR7","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","volume":"63","author":"MS Kuchay","year":"2020","unstructured":"M.S. Kuchay, S. Krishan, S.K. Mishra, N.S. Choudhary, M.K. Singh, J.S. Wasir, P. Kaur, H.K. Gill, T. Bano, K.J. Farooqui, A. Mithal, Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 63, 2434\u20132445 (2020)","journal-title":"Diabetologia"},{"key":"4007_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/met.2008.0034","volume":"6","author":"LE Simental-Mend\u00eda","year":"2008","unstructured":"L.E. Simental-Mend\u00eda, M. Rodr\u00edguez-Mor\u00e1n, F. Guerrero-Romero, The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord 6, 299\u2013304 (2008)","journal-title":"Metab Syndr Relat Disord"},{"key":"4007_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"G. Bedogni, S. Bellentani, L. Miglioli, F. Masutti, M. Passalacqua, A. Castiglione, C. Tiribelli, The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6, 33 (2006)","journal-title":"BMC Gastroenterol"},{"key":"4007_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"J.H. Lee, D. Kim, H.J. Kim, C.H. Lee, J.I. Yang, W. Kim, Y.J. Kim, J.H. Yoon, S.H. Cho, M.W. Sung, H.S. Lee, Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 42, 503\u2013508 (2010)","journal-title":"Dig Liver Dis"},{"key":"4007_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.37349\/emed.2023.00121","volume":"4","author":"D Ioannidou","year":"2023","unstructured":"D. Ioannidou, E.S. Makri, S.A. Polyzos, C. Ntenti, D. Agapakis, G. Germanidis, A. Goulas, An association study of the PNPLA3 I148M polymorphism (rs738409) with serum lipids in patients with dyslipidemia. Explor Med. 4, 16\u201322 (2023)","journal-title":"Explor Med."},{"key":"4007_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jcjd.2016.01.002","volume":"40","author":"D Agapakis","year":"2016","unstructured":"D. Agapakis, C. Savopoulos, K.E. Kypreos, E. Gbandi, S. Iliadis, A.I. Hatzitolios, A. Goulas, Association of the CETP Taq1B and LIPG Thr111IlE polymorphisms with glycated hemoglobin and blood lipids in newly diagnosed hyperlipidemic patients. Can J Diabetes 40, 515\u2013520 (2016)","journal-title":"Can J Diabetes"},{"key":"4007_CR13","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.2337\/dc13-2759","volume":"37","author":"G Umpierrez","year":"2014","unstructured":"G. Umpierrez, S. Tof\u00e9 Povedano, F. P\u00e9rez Manghi, L. Shurzinske, V. Pechtner, Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diab Care 37, 2168\u20132176 (2014)","journal-title":"Diab Care"},{"key":"4007_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s12020-020-02193-9","volume":"68","author":"S Qie","year":"2020","unstructured":"S. Qie, X. Li, X. Wang, Y. Liu, J. Li, G. Liu, Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials. Endocrine 68, 508\u2013517 (2020)","journal-title":"Endocrine"},{"key":"4007_CR15","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/dom.12702","volume":"18","author":"C Wysham","year":"2016","unstructured":"C. Wysham, B. Guerci, D. D\u2019Alessio, N. Jia, F.T. Botros, Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes. Diab Obes Metab 18, 1138\u20131142 (2016)","journal-title":"Diab Obes Metab"},{"key":"4007_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1053\/j.gastro.2023.11.018","volume":"166","author":"E Urias","year":"2024","unstructured":"E. Urias, N.R. Tedesco, A. Oliveri, C. Raut, E.K. Speliotes, V.L. Chen, PNPLA3 risk allele association with ALT response to semaglutide treatment. Gastroenterology 166, 515\u2013517.e512 (2024)","journal-title":"Gastroenterology"},{"key":"4007_CR17","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jdiacomp.2016.01.013","volume":"30","author":"H Quan","year":"2016","unstructured":"H. Quan, H. Zhang, W. Wei, T. Fang, Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus. J Diab Complicat 30, 686\u2013692 (2016)","journal-title":"J Diab Complicat"},{"key":"4007_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/dom.13086","volume":"20","author":"B Gallwitz","year":"2018","unstructured":"B. Gallwitz, S. Dagogo-Jack, V. Thieu, L.E. Garcia-Perez, I. Pavo, M. Yu, K.E. Robertson, N. Zhang, F. Giorgino, Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diab Obes Metab 20, 409\u2013418 (2018)","journal-title":"Diab Obes Metab"},{"key":"4007_CR19","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1038\/s41591-023-02553-8","volume":"29","author":"A Cherubini","year":"2023","unstructured":"A. Cherubini, M. Ostadreza, O. Jamialahmadi, S. Pelusi, E. Rrapaj, E. Casirati, G. Passignani, M. Norouziesfahani, E. Sinopoli, G. Baselli, C. Meda, P. Dongiovanni, D. Dondossola, N. Youngson, A. Tourna, S. Chokshi, E. Bugianesi, S. Della Torre, D. Prati, S. Romeo, L. Valenti, Interaction between estrogen receptor-\u03b1 and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women. Nat Med 29, 2643\u20132655 (2023)","journal-title":"Nat Med"},{"key":"4007_CR20","doi-asserted-by":"publisher","first-page":"E237","DOI":"10.25011\/cim.v35i4.17153","volume":"35","author":"Q Li","year":"2012","unstructured":"Q. Li, H.Q. Qu, A.R. Rentfro, M.L. Grove, S. Mirza, Y. Lu, C.L. Hanis, M.B. Fallon, E. Boerwinkle, S.P. Fisher-Hoch, J.B. McCormick, PNPLA3 polymorphisms and liver aminotransferase levels in a Mexican American population. Clin Invest Med 35, E237\u2013E245 (2012)","journal-title":"Clin Invest Med"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04007-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-04007-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04007-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T12:52:52Z","timestamp":1737031972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-04007-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["4007"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-04007-8","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the Bioethics Committee of School of Medicine, Aristotle University of Thessaloniki, Greece (1733\/18-01-2022 and 3588\/18-01-2022), as well as by the Scientific Committee of the Papageorgiou Hospital, Thessaloniki, Greece (351\/16-2-2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}